Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types

Nicholas Willumsen1 · Christina Jensen1 · George Green2 · Neel I. Nissen1 · Jaclyn Neely2 · David M. Nelson2 · Rasmus S. Pedersen1 · Peder Frederiksen1 · Inna M. Chen3 · Mogens K. Boisen2 · Astrid Z. Johansen3 · Daniel H. Madsen4 · Inge Marie Svane4 · Allan Lipton5 · Kim Leitzel5 · SuhaI M. Ali6 · Janine T. Erler7 · Daan P. Hurkmans8 · Ron H. J. Mathijssen9 · Joachim Aerts10 · Mohammed Eslam11 · Jacob George11 · Claus Christiansen1 · Mina J. Bissel12 · Morten A. Karsdal1

Received: 7 December 2021 / Revised: 15 February 2022 / Accepted: 28 February 2022 / Published online: 25 March 2022 © The Author(s) 2022

Abstract

Due to activation of fibroblast into cancer-associated fibroblasts, there is often an increased deposition of extracellular matrix and fibrillar collagens, e.g. type III collagen, in the tumor microenvironment (TME) that leads to tumor fibrosis (desmoplasia). Tumor fibrosis is closely associated with treatment response and poor prognosis for patients with solid tumors. To assure that the best possible treatment option is provided for patients, there is medical need for identifying patients with high (or low) fibrotic activity in the TME. Measuring unique collagen fragments such as the pro-peptides released into the bloodstream during fibrillar collagen deposition in the TME can provide a non-invasive measure of the fibrotic activity. Based on data from 8 previously published cohorts, this review provides insight into the prognostic value of quantifying tumor fibrosis by measuring the pro-peptide of type III collagen in serum of a total of 1692 patients with different solid tumor types and discusses the importance of tumor fibrosis for understanding prognosis and for potentially guiding future drug development efforts that aim at overcoming the poor outcome associated with a fibrotic TME.

Keywords Tumor fibrosis · Serum biomarker · Fibroblast · Collagen · Prognosis

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| α-SMA        | Alpha smooth muscle actin |
| BMI          | Body mass index |
| CAF          | Cancer-associated fibroblast |
| CBD          | Collagen-binding domain |
| DFS          | Disease free survival |

| Abbreviation | Description |
|--------------|-------------|
| ECM          | Extracellular matrix |
| FAP          | Fibroblast activation protein |
| FDA          | Food and Drug Administration |
| HR           | Hazard ratio |
| IHC          | Immunohistochemistry |
| IL           | Interleukin |

1 Nordic Bioscience, Herlev Hovedgade 205-207, 2730 Herlev, Denmark
2 Bristol Myers Squibb, Princeton, NJ, USA
3 Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
4 Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
5 Penn State Hershey Medical Center, Hershey, PA, USA
6 Lebanon VA Medical Center, Lebanon, PA, USA
7 Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark
8 Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands
9 Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
10 Department of Pulmonology, Erasmus University Medical Center, Rotterdam, The Netherlands
11 Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia
12 Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
Introduction to the extracellular matrix (ECM) and collagens in the tumor microenvironment (TME)

The tumor microenvironment (TME) is important for tumor progression and patient survival. The extracellular matrix (ECM) comprises an important component of the TME in addition to the tumor cells, stromal cells and immune infiltrate [1]. The ECM is the non-cellular component of tissues and organs that provides crucial physical, bio-mechanical and bio-chemical properties that is required for tissue morphogenesis, differentiation and homeostasis [2]. The major components of the ECM are the collagens, of which 28 different types have been described, each with a unique role in supporting the tissue microarchitecture [3]. Under normal conditions, a homeostatic state of collagen turnover is maintained by a refined balance between synthesis, degradation and post-translational modifications that maintains tissue integrity. In contrast to a normal healthy stroma, this collagen homeostasis is disrupted in the TME as the composition and quality of the tumor tissue becomes altered [4]. Changes in the composition of the ECM/collagens have been shown to modulate the hallmarks of cancer and are thought to play a vital role in tumor progression and metastasis as well as in defining the likelihood of responding to anti-cancer therapies [5–8].

Overall, the ECM can be divided into the basement membrane and the interstitial matrix [2, 3]. The basement membrane underlies the epithelial and endothelial cells and supports glandular structures and blood vessels [9]. It is a relatively loose ECM with so-called network forming collagens, where type IV collagen is the most abundant protein together with laminins. The basement membrane allows nutrients and oxygen to diffuse through. In the context of cancer, loss of basement membrane structures has been associated with tumor cell invasion and angiogenesis [10, 11]. It has been well investigated and documented since the early discoveries of Mina Bissel and colleagues that the basement membrane is important for cell function and can even revert a malignant cell phenotype [12, 13]. Recent findings support that the basement membrane is key for determining the metastatic potential of cancer [14]. Cellular invasion through the basement membrane is a key factor in tumorigenesis and is driven primarily by the increased matrix metalloprotease (MMP) activity in the TME that degrade e.g. type IV collagen and alters cellular adhesion and integrin-signaling and hereby affects cell behavior [4, 15–21].

Below the basement membrane appears the interstitial matrix [2, 3]. The interstitial matrix consists of a fibrillar collagen network of type I, III, V, and XI collagens that form a 3D lattice to support tissue structure and cell function. The two major fibrillar collagens in the interstitial matrix are type I collagen and type III collagen. Type I collagen is the most abundant protein in the body and can be found in bone and connective tissues [3]. Type III collagen is the second most abundant collagen, found primarily in connective tissues.

In the TME, there is often an increased interstitial matrix deposition and remodeling of fibrillar collagens due to activation of quiescent fibroblasts into cancer-associated fibroblasts (CAFs) that not only synthesize excess amount of ECM and collagen but also contribute to MMP mediated fibrillar collagen degradation [22]. This chronic-active scarring process is also known as tumor fibrosis, or desmoplasia. As described below, tumor fibrosis has been shown to be closely associated with tumor aggressiveness, treatment response and prognosis for patients. However, we are only beginning to understand the potential impact of a fibrotic TME, the ECM and associated collagens.

Major drivers and impact of fibrosis in the TME

The major pathological signature of tumor fibrosis is a fibrous connective tissue of interstitial matrix formed by proliferation and activation of fibroblasts which takes place inside, adjacent to, and around a solid tumor [23]. All the fibrillar collagens associated with tumor fibrosis are produced by CAFs resulting in increased deposition of a cross-linked dense and stiff collagen matrix that is impermeable for treatment, nutrients, and oxygen and therefore associated with poor outcome [24–26]. The CAF and tumor fibrosis biology builds on lessons learned from fibrotic disorders such as idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, primary sclerosing cholangitis, systemic sclerosis as well as liver, heart, lung and kidney fibrosis [4, 5, 27–35] and it has been shown that ECM turnover is generally higher in liver cancer versus cirrhosis, lung cancer versus idiopathic pulmonary fibrosis and pancreatic cancer versus chronic pancreatitis [36–38]. The CAFs promote tumorigenesis by contributing to ECM remodeling as well as secreting e.g. cytokines and growth factors to crosstalk with the immune cells and cancer cells. Among the growth
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can...

Factors and cytokines, transforming growth factor-β (TGF-β) is considered as the major pro-fibrotic cytokine and inducer of fibrogenesis because it promotes CAF development and increased collagen synthesis [39, 40]. Other cytokines such as interleukin (IL)-4, IL-13, and platelet-derived growth factor (PDGF) are pro-fibrotic as well and affect collagen expression [41, 42]. MMPs can also activate and release latent TGF-β stored in the ECM and hence can drive tumor fibrosis indirectly [43].

Tumor fibrosis may result in reduced treatment effect by forming a barrier for treatment that hinders drug penetration [26]. The interaction between tumor fibrosis, CAFs and immune cells infiltrating the tumor microenvironment directly and indirectly inhibit antitumor immunity with the activation of fibroblasts and excessive collagen deposition linked to the lack of T-cell infiltration and activity in the tumor that is a prerequisite for efficient response to immunotherapies [44–50]. This fibrosis associated T-cell exclusion from the tumor core may be due to entrapment in the collagen-rich peritumoral stroma and/or due to leukocyte-specific collagen receptor 1 (LAIR1) dependent T-cell exhaustion [48, 51, 52]. Tumor fibrosis may also limit the anti-tumor activity of effector T-cells by mediating the recruitment, and the activation of secretory programs of immunosuppressive cells such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) [47, 53, 54]. Higher collagen density within the tumor ECM promotes the polarization of TAMs to a more tumor-promoting functional phenotype characterized by enhanced expression of immunosuppressive genes and secreted proteins [55]. Furthermore, single cell sequencing studies of tumors reveal that similar to CAFs, TAMs are also capable of upregulating the expression of ECM genes, suggesting that they may themselves influence the fibrotic composition of the tumor stroma [56]. Figure 1 illustrates this major pathological tissue signature and associated clinical impact of tumor fibrosis.

Quantifying tumor fibrosis in a liquid biopsy: potential prognostic value of measuring type III collagen pro-peptides non-invasively in patients with cancer

The common standard for assessing tumor fibrosis in patients diagnosed with cancer is by use of Sirius red or trichrome staining of total collagen content in tissue biopsies, or by staining for type I collagen and III collagen with antibodies for more detailed immunohistochemical assessments. The measurement of fibroblast activation markers, e.g. alpha smooth muscle actin (α-SMA) and fibroblast activation protein (FAP), and stromal gene signatures in the immuno-oncology setting, recently have been added to this portfolio [48, 51, 52, 56–58]

To describe the dynamics of tumor fibrosis, a range of novel technologies are emerging which quantify specific collagen fragments in blood [59–61]. By targeting unique fibrillar collagen degradation fragments, or pro-peptides, one may provide a dynamic measure of tumor fibrosis with the ability to quantify the collagen turnover or synthesis rate (fibrotic activity). As collagens are degraded or built into fibers, there is a release of unique epitopes that may provide information about the ongoing pathological processes of damage and repair with some epitopes being released during collagen formation (e.g. pro-peptides) and other epitopes being...
released during collagen degradation (e.g. MMP-generated peptide fragments) [62]. Such epitopes/peptides can be identified by mass spectrometry, then targeted by antibodies, and ultimately quantified by an immunoassay or alike. As the bone consist primarily of type I collagen, the pro-peptide from type I collagen is often used as a surrogate for bone formation whereas the degradation fragment CTX-I, is often used as a surrogate for bone degradation. As type III collagen is almost exclusively found in soft tissue and not in bone, and is derived from activated fibroblasts, it may be a superior fibrosis marker than the pro-peptide from type I collagen. An illustration of the biology and dynamics supporting this non-invasive biomarker approach to quantify tumor fibrosis is shown in Fig. 2. The rationale for investigating the prognostic value of quantifying tumor fibrosis through measurements of type III collagen fragments emerged through a hypothesis-driven approach supported by observations that type III collagen pro-peptides have been found significantly increased (> fivefold) in conditioned media from the ‘scar-in-a-jar’ in vitro culture of highly fibrotic CAFs as compared to normal fibroblast [63], and highly elevated in fibrotic disorders [4]. The monoclonal antibody used to quantify the pro-peptide of type III collagen in all the studies presented here was originally described and developed by Nielsen et al., to reflect true formation of type III collagen [64]. As this particular monoclonal antibody was raised specifically against the N-protease cleavage site of the procollagen (i.e. only targeting released pro-peptides) it differs from other available similar assays that either employs polyclonal antibodies or monoclonal antibodies targeting internal sequences of the pro-peptide and therefore cannot differentiate between type III collagen formation and degradation as the removal of the pro-peptide is sometimes incomplete resulting in abnormal fibrils that are prone to rapid metabolic turnover [65–68].

Data from clinical studies encompassing 1692 patients suffering from breast cancer, pancreatic cancer, colorectal cancer, liver cancer and malignant melanoma are summarized in the forest plot in Fig. 3. In all studies, the patients with high net fibrotic activity (type III collagen pro-peptides) at baseline had poor overall survival (OS). Approximately, two to threefold increased risk of death was observed in patients with high levels of type III collagen pro-peptides. An overview of the different patient cohorts are depicted in Table 1.

All studies, except Chen et al., applied cutoffs that were based on dichotomizing patients in to ‘high’ and ‘low’ levels of type III collagen pro-peptides and the exact cutoff value varied from study to study. In the study by Chen et al., the hazard ratio (HR) calculations were based on
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can...

Importantly, full clinical utility of type III collagen pro-peptides as a prognostic tumor fibrosis biomarker needs additional exploration of a specific cut-off per indication and treatment modality which warrants additional prospective studies. Altogether, measuring fibroblast derived type III collagen pro-peptides in serum seems not only to be a tumor agnostic, prognostic, tumor fibrosis biomarker (liquid biopsy) but also points to the need of focusing a continuous scale and may therefore partly explain the relatively lower HR compared to the other study cohorts.

Table 1

| Study                  | Cancer type                        | Therapy                        | No. of pts | Sample source | Cut-off       | HR for OS | 95% CI | p value |
|------------------------|------------------------------------|--------------------------------|------------|---------------|---------------|-----------|--------|---------|
| Lipton et al. [119]    | Breast cancer, metastatic, ER/PR + | Letrozole                      | 148        | Serum         | 29.5 ng/ml   | 1.95      | 1.22–3.09 | 0.005   |
| Lipton et al. [119]    | Breast cancer, metastatic, HER2 +  | Trastuzumab                    | 55         | Serum         | 25.5 ng/ml   | 3.37      | 1.67–6.80 | 0.001   |
| Willumsen et al. [120] | Pancreatic cancer, advanced         | Chemotherapy (5-FU)            | 176        | Serum         | 10.4 ng/ml   | 2.01      | 1.33–3.05 | 0.001   |
| Chen et al. [38]       | Pancreatic cancer, all stages       | Chemotherapy (SoC)             | 809        | Serum         | 100 ng/ml/ increase | 1.28      | 1.11–1.49 | < 0.01  |
| Jensen et al. [121]    | Melanoma, metastatic               | Ipilimumab                     | 66         | Serum         | 19.6 ng/ml   | 2.13      | 1.12–4.04 | 0.021   |
| Hurkmans et al. [122]  | Melanoma, metastatic               | Nivolumab or Pembrolimusab     | 107        | Serum         | 12.6 ng/ml   | 2.41      | 1.26–4.60 | 0.008   |
| Jensen et al. [36]     | Liver cancer, all stages            | Various                        | 79         | EDTA plasma   | 23.9 ng/ml   | 2.12      | 1.10–4.05 | 0.024   |
| Nissen et al. [123]    | Colorectal cancer, metastatic      | Chemotherapy + Bevacizumab      | 252        | Serum         | 13.2 ng/ml   | 2.01      | 1.54–2.64 | <0.0001 |

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, 5-FU 5-Fluorouracil, SoC standard of care, HR hazard ratio, CI confidence intervals
particularly on the fibroblast-derived interstitial matrix in the context of cancer [61, 63, 69, 70].

It is worth emphasizing that most of the studies listed here included patients with advanced/metastatic disease which mostly carries a very poor prognosis. Nonetheless, based on the data published from the study by Chen et al., including approximately 800 patients with pancreatic cancer this tumor fibrosis prognostic signature seems independent of stage of disease and tumor burden [38]. In addition, preliminary results of type III collagen pro-peptides measured in the early colorectal cancer setting showed associations with disease-free survival (DFS) as defined by the time interval between surgery and recurrence and is aligned with the fact that ECM composition and quality impacts and modulates the metastatic potential and hence risk of relapse (prognosis) [7]. This suggest that fibrotic activity in patients with cancer should be considered alongside more commonly assessed risk factors when attempting to provide the best possible prognosis for patients. Of interest, measuring type III collagen pro-peptides in serum was recently reported to be stable under conditions conforming with hospital sample-handling requirements and with levels not associated with sex, age, body mass index (BMI), or ethnicity [71]. In addition to the solid tumor types addressed here, elevated serum levels of collagen fragments have been found in patients with head and neck cancer, non-small cell lung cancer, gastric cancer and ovarian cancer supporting the tumor agnostic nature of altered collagen turnover and tumor fibrosis [37, 72–76].

There is a major medical need for defining this ‘fibrotic’ group of cancer patients. The first step is to differentiate those with ongoing tumor fibrosis from those without. A liquid biopsy approach as presented here for evaluating collagen peptides associated with tumor fibrosis may provide a novel and clinically applicable tool for patient stratification according to their fibrotic activity. As with any liquid biopsy, given its systemic nature there is a potential need of a concurrent (or upfront) tissue-based assessment for full histological diagnosis. However, a liquid biopsy-based approach is less invasive, quicker, and generally more frequently accessible than the gold standard tumor biopsy-based approach (which is further limited by tumor heterogeneity and is challenging, or impossible, to obtain) [77].

Future perspectives

As highlighted above, the prognostic value of quantifying tumor fibrosis non-invasively can be obtained by measuring the pro-peptide of type III collagen in serum/plasma. The prognostic value was demonstrated across various solid tumor types including notoriously hard to treat cancers such as pancreatic cancer, and prevalent cancer types such as breast cancer, colorectal cancer, liver cancer and malignant melanoma, and for multiple treatment modalities. This supports the importance of fibrosis as a tumor agnostic process and points toward a broadly applicable biomarker approach for future clinical cancer research. While type III collagen pro-peptides is reflective of tumor fibrosis and CAF activity, type III collagen has also been shown to maintain tumor dormancy depending on context and composition [69]. Similarly, type VI collagen, another fibroblast derived collagen, can be both pro- and anti-tumorigenic, depending on context [69, 78]. In fact, there are emerging subtypes of CAFs, fibrosis types, and collagen profiles, which may have a unique function in either supporting or inhibiting cancer growth depending on context. Fibroblasts heterogeneity and the existence of different fibroblast subsets, their transcriptional profiles, and lineages are being extensively studied and where in particular iCAFs and myCAFs has been introduced as two subtypes of CAFs that play an inflammatory and myofibroblast like role, respectively, and differ in their functionality and localization within the TME [79–91]. Moreover, in several mouse models, in particular PDAC models, it has been shown that attenuating collagen synthesis in cancer associated fibroblasts increases tumor growth and spread, but at the same time may also leave tumors more prone to therapeutic intervention [92–95]. Altogether indication that there are not only good and bad fibroblast subtypes but also good and bad collagens [4].

The impact that tumor fibrosis may have on clinical outcome and in shaping the future of clinical cancer research needs to be considered. A significant percentage of patients with cancer that are included in clinical trials do not benefit from treatment, and consequently, there is a need for predictive biomarkers to treat the right patients with the right drugs at the right time [50, 96]. Intriguingly, type III collagen turnover, measured retrospectively at baseline in plasma from a discovery and validation cohort of patients with metastatic pancreatic cancer has been shown to have the capacity to also predict treatment benefit of a stromal modifier (PEGPH20) when used in combination with chemotherapy hereby providing evidence for potential predictive value [97]. In detail, both the objective response rate and survival outcomes improved significantly with PEGPH20 as an add-on to chemotherapy compared to chemotherapy alone in the patients with a high ratio of type III collagen degradation to formation, whereas in the remaining patients with a low ratio, there was no effect of adding PEGPH20 to chemotherapy. Hence, a tumor fibrosis liquid biopsy may not only be used prognostically but may also predict response to anti-fibrotic treatments. Another clinical utility may be to identify high risk patients in earlier stages of disease that may need more aggressive treatments and frequent monitoring.

In recent years, 85% of US Food and Drug Administration (FDA) approved cancer treatments have been related to the cancer-immunity cycle [98]. And while immune checkpoint
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can...
tectual property pending at Pamgene. JA declares to have patents or other related intellectual property at Amphi dangerous and travels expenses paid by MSD. ME declares paid honoraria from Sanofi and a consultancy/ advisory role at Pfizer. JG declares paid honoraria and a consultancy/advisory role at Roche, MSD, Pfizer, Abbvie, AstraZeneca, Novartis, Pharmaxis, Cincera, Novo, Gilead, Norgine, Eisai. CC have stock ownership and patents in Nordic Bioscience. MK is employed and have stock ownership and patents in Nordic Bioscience.

Ethics approval and consent to participate Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125:5591–5596
2. Frantz C, Stewart KM, Weaver VM (2010) The extracellular matrix at a glance. J Cell Sci 123:4195–4200
3. Karsdal M (2016) Biochemistry of collagens: structure, function and biomarkers. Academic Press, Cambridge
4. Karsdal MA, Nielsen SH, Leeming DJ, Langholm LL, Nielsen MJ, Manon-Jensen T et al (2017) The good and the bad collagens of fibrosis—their role in signaling and organ function. Adv Drug Deliv Rev 121:43–56
5. Pickup MW, Mouw JK, Weaver VM (2014) The extracellular matrix modulates the hallmarks of cancer. EMBO J 15:1243–1253
6. Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart H, Jürgenson HJ, Engelholm LH et al (2022) Uncovering mediators of collagen degradation in the tumor microenvironment. Matrix Biol Plus 13:100101
7. Lin S-C, Kaufmann WK, Brandt BH, Hsieh S-L, Lin W-W, End C et al (2011) Desmplasia. Encyclopedia of Cancer [Internet]. Springer, Berlin, pp 1093–1095
8. Longo DL, Rockey DC, Bell PD, Hill JA (2015) Fibrosis—a common pathway to organ injury and failure. N Engl J Med 372:1138–1149
9. Pankova D, Chen Y, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M et al (2016) Cancer-associated fibroblasts induce a collagen cross-link switch in tumor stroma. Mol Cancer Res 14:287–295
10. Yamauchi M, Barker TH, Gibbons DL, Kurie JM (2018) The fibrotic tumor stroma. J Clin Investig 128:16–25
11. Hirschfeld GM, Chazollères O, Drenth JP, Thoburn D, Harrison SA, Landis CS et al (2019) Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol 70:483–493
12. Bonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15:786–801
13. Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen AC et al (2013) Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 11:70–92
14. Sahai E, Assisaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM et al (2020) A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 20:174–186
15. Villesen IF, Daniels SJ, Leeming DJ, Karsdal MA, Nielsen MJ (2020) Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis. Aliment Pharmacol Ther 52:85–97
32. Reese-Petersen AL, Olesen MS, Karsdal MA, Svendsen JH, Genovese F (2020) Atrial fibrillation and cardiac fibrosis: a review on the potential of extracellular matrix proteins as biomarkers. Matrix Biol 91–92:188–203
33. Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R et al (2020) Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int 40:736–750
34. Karsdal MA, Kraus VB, Shevell D, Bay-Jensen AC, Schattenberg J, Rambabu Surabattula R et al (2021) Profiling and targeting connective tissue remodeling in autoimmunity—a novel paradigm for diagnosing and treating chronic diseases. Autoimmun Rev 20:102706
35. Kristensen JH, Karsdal MA, Genovese F, Johnson S, Svensson B, Jacobsen S et al (2014) The role of extracellular matrix quality in pulmonary fibrosis. Respir Res 88:479–499
36. Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R et al (2020) Cross-linked multimeric pro-peptides of type III collagen (PC3X) in hepatocellular carcinoma—a biomarker that provides additional prognostic value in AFP positive patients. J Hepatocell Carcinoma 7:301–313
37. Willumsen N, Bager CL, Leeming DJ, Smith V, Christiansen C, Jensen C, Holm Nielsen S, Eslam M, Genovese F (2020) Atrial fibrillation and cardiac fibrosis. Matrix Biol 91–92:188–203
38. Willumsen N, Bager CL, Leeming DJ, Smith V, Christiansen C, Karsdal MA et al (2014) Serum biomarkers reflecting specific tissue remodeling processes are valuable diagnostic tools for lung cancer. Cancer Med 3:1136–1145
39. Chen IM, Willumsen N, Dehlerodt C, Johansen AZ, Jensen BV, Hansen CP et al (2019) Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Int J Cancer 146:2913–2922
40. Bourgot I, Primac I, Louis T, Noël A, Maquoi E (2020) Reciprocal interplay between fibroblasts and collagen-binding integrins: implications in cancer progression and metastasis. Front Oncol 10:1–28
41. Borthwick LA, Wynn TA, Fisher AJ (2013) Cytokine-mediated tissue fibrosis. Biochim Biophys Acta Mol Basis Dis 1832:1049–1060
42. Ricard-Blum S, Baffet G, Théret N (2018) Molecular and tissue alterations of collagen in fibrosis. Matrix Biol 68–69:122–149
43. Krstic J, Santibanez JF (2014) Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. Sci World J 2014:521754
44. Mao X, Xu J, Wang W, Liang C, Hua J, Liu J et al (2021) Cross-talk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 13:1–30
45. Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74–80
46. Provenzano PP, Inman DR, Eticheiri KW, Knittel JG, Yan L, Rueden CT et al (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6:11
47. Jiang H, Hegde S, DeNardo DG (2017) Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol Immunother 66:1037–1048
48. Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA et al (2020) Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun 11:4520
49. Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA et al (2016) Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 22:851–860
50. Mushiaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z (2018) Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. JITC 6:1–14
51. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y et al (2018) TGFβ attenuates tumor response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544–548
52. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domech J et al (2018) EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun 9:1–12
53. Jayasingam SD, Citrartan M, Thang TH, Mat Zin AA, Ang KC, Ch'ng ES (2020) Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol 9:1512
54. DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol [Internet] 19:369–382
55. Larsen AMH, Kuczek DE, Kalvisa A, Siersbæk MS, Thorset M-L, Johansen AZ et al (2020) Collagen density modulates the immunosuppressive functions of macrophages. J Immunol 205:1461–1472
56. Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD (2018) TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun 9:4692
57. Okrah K, Tarighat S, Liu B, Koeppen H, Wagle MC, Cheng G et al (2018) Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology. NPI Precis Oncol 15:25
58. Han C, Liu T, Yin R (2020) Biomarkers for cancer-associated fibroblasts. Biomark Rev 8:64
59. Cavaco ACM, Dâmaso S, Casimiro S, Costa L (2020) Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis. Cancer Metastasis Rev 39:603–623
60. Giussani M, Triulzi T, Sozzi G, Tagliabue E, Giussani M, Triulzi T et al (2019) Tumor extracellular matrix remodeling: new perspectives as a circulating tool in the diagnosis and prognosis of solid tumors. Cells 8:81
61. Nissen NH, Karsdal M, Willumsen N (2019) Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res 38:115
62. Karsdal M, Genovese F, Rasmussen D, Bay-Jensen A, Mortensen J, Holm Nielsen S et al (2021) Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes. Clin Biochem 97:11–24
63. Nissen NH, Johansen AZ, Chen I, Johansen JS, Pedersen RS, Hansen CP et al (2022) Collagen biomarkers quantify fibroblast activity in vitro and predict survival in patients with pancreatic ductal adenocarcinoma. Cancers 14:819
64. Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, Zheng Q et al (2013) The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 5:303–315
65. Rohde H, Vargas L, Eckhardt KH, Bruguera M, Templ R (1979) Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Investig 9:451–459
66. Brooks DG, Steinert C, Gerl M, Knolle J, Neubauer HP, Günzler V (1993) A radioimmunoassay for the N-terminal propeptide of rat procollagen type III. Application to the study of the uptake of the N-terminal propeptide of procollagen type III in isolated perfused rat liver. Matrix 13:381–387
67. Niemelä O, Risteli L, Parkkinen J, Risteli J (1985) Purification and characterization of the N-terminal propeptide of human type III procollagen. Biochem J 232:145–150
68. Wang W-M, Ge G, Lim NH, Nagase H, Greenspan DS (2006) TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. Biochem J 398:515–519

69. Di Martino JS, Nobre AR, Mondal C, Taha I, Farias EF, Fertig EJ et al (2022) A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. Nat Cancer 3:90–107

70. Belhabib I, Zaghoudi S, Lac C, Bousquet C, Jean C (2021) Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy? Cancers 13:3466

71. Erhardtse E, Rasmussen DGK, Frederiksen P, Leeming DJ, Shevell D, Gluud LL et al (2021) Determining a healthy reference range and factors potentially influencing PRO-C3—a biomarker of liver fibrosis. JHEP Rep 3:100317

72. Nurmeniemi S, Koivula M-KK, Nyberg P, Tervahartiala T, Sorsa T, Mattila PS et al (2012) Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma. Oral Oncol 48:136–140

73. Nielsen SH, Willumsen N, Brix S, Sun S, Manon-Jensen T, Thorlacius-Ussing J, Manon-Jensen T, Sun S, Leeming DJ, Sand Brachmann CB, Zhang Y, Zavodovskaya M, Hu J, Maltzman Bager CL, Willumsen N, Leeming DJ, Smith V, Karsdal MA, Öhlund D, Elyada E, Tuveson DA (2021) Diversity and biology of cancer-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719–734

74. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA et al (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:735–747

75. Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Afso S et al (2021) Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Investig 131:e146987

76. Chen Y, Kim J, Yang S, Wang H, Wu C-J, Sugimoto H et al (2021) Type I collagen deletion in sMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell 39:548–565

77. Willumsen N, Thomsen LB, Bager CL, Jensen C, Karsdal MA (2018) Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immune-therapeutic anti-tumor modalities. Cancer Immunol Immunother 67:1–12

78. Wang S, Bager CL, Karsdal MA, Chondros D, Taverna D, Willumsen N (2021) Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegyvorhyaluronidase alfa. J Transl Med 19:39

79. de Miguel M, Calvo E (2020) Clinical challenges of immune checkpoint inhibitors. Cancer Cell 38:326–333

80. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH et al (2018) The immune landscape of cancer. Immunity 48:812–830

81. Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20:651–668

82. Bagaaev A, Kotlov N, Nomi K, Svekolkin V, Gafurov A, Isaeva MA et al (2021) Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39:845–865

83. Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R et al (2021) Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184:596–614

84. Ospiov A, Lim SJ, Popovic A, Azad NS, Laheru DA, Zheng L et al (2020) Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: a meta-regression analysis. Clin Cancer Res 26:4842–4851
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can…

104. Wu Y, Xu J, Du C, Wu Y, Xia D, Lv W et al (2019) The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis. Front Oncol 9:1161

105. Zhu J, Zhang T, Li J, Lin J, Liang W, Huang W et al (2019) Association between tumor mutation burden (TMB) and outcomes of cancer patients treated with PD-1/ PD-L1 inhibitions: a meta-analysis. Front Pharmacol 10:673

106. Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7:1–8

107. Liu T, Han C, Wang S, Fang P, Ma Z, Xu L et al (2019) Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol 12:86

108. Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA et al (2016) Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 22:1–13

109. Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P et al (2017) Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med 9:eaan0401

110. Ishihara J, Ishihara A, Sasaki K, Lee SSY, Williford JM, Yasui M et al (2019) Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med 11:eaau3259

111. Mansurov A, Ishihara J, Hosseinchi P, Potin L, Marchell TM, Ishihara A et al (2020) Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat Biomed Eng 4:531–543

112. Ciardiello D, Elez E, Tabernero J, Seoane J (2020) Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. Ann Oncol 31:1336–1349

113. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK (2011) Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci 108:2909–2914

114. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY et al (2019) Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol 5:1020–1027

115. Han H, Hou Y, Chen X, Zhang P, Kang M, Jin Q et al (2020) Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy. J Am Chem Soc 142:4944–4954

116. Froeling FEM, Kocher HM (2015) Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression. Gastroenterology 148:849–850

117. Hauge A, Rofstad EK (2020) Antifibrotic therapy to normalize the tumor microenvironment. J Transl Med 18:207

118. Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M et al (2020) Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Investig 130:4704–4709

119. Lipton A, Leitzel K, Ali SM, Polimera HV, Nagabhauru V, Marks E et al (2018) High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. Int J Cancer 143:3027–3034

120. Willumsen N, Ali SM, Leitzel K, Drabick JJ, Yee N, Polimera HV et al (2019) Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Sci Rep 9:19761

121. Jensen C, Madsen DH, Hansen M, Schmidt H, Svane IM, Karsdal MA et al (2018) Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. J Immunother Cancer 6:1–10

122. Hurkmans DP, Jensen C, Koolen SLW, Aerts J, Karsdal MA, Mathijsens RHJ et al (2020) Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. J Immunother Cancer 8:e001193

123. Nissen NI, Kehlet S, Boisen MK, Liljefors M, Jensen C, Johansen AZ et al (2021) Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab. Sci Rep 11:865

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.